Light-activated nanoparticles can supercharge current antibiotics

Light-activated nanoparticles can supercharge current antibiotics
CU Boulder researcher Colleen Courtney (left) speaks with Assistant Professor Anushree Chatterjee (right) inside a lab in the BioFrontiers Institute. Credit: University of Colorado Boulder

Light-activated nanoparticles, also known as quantum dots, can provide a crucial boost in effectiveness for antibiotic treatments used to combat drug-resistant superbugs such as E. coli and Salmonella, new University of Colorado Boulder research shows.

Multi-drug resistant pathogens, which evolve their defenses faster than new can be developed to treat them, cost the United States an estimated $20 billion in direct healthcare costs and an additional $35 billion in lost productivity in 2013.

CU Boulder researchers, however, were able to re-potentiate existing for certain clinical isolate infections by introducing nano-engineered dots, which can be deployed selectively and activated or de-activated using specific wavelengths of light.

Rather than attacking the infecting bacteria conventionally, the dots release superoxide, a chemical species that interferes with the bacteria's metabolic and cellular processes, triggering a fight response that makes it more susceptible to the original antibiotic.

"We've developed a one-two knockout punch," said Prashant Nagpal, an assistant professor in CU Boulder's Department of Chemical and Biological Engineering (CHBE) and the co-lead author of the study. "The bacteria's natural fight reaction [to the dots] actually leaves it more vulnerable."

The findings, which were published today in the journal Science Advances, show that the dots reduced the effective antibiotic resistance of the clinical isolate infections by a factor of 1,000 without producing adverse side effects.

Researchers at CU Boulder's BioFrontiers Institute have created light-activated nanoparticles, also known as quantum dots, which provide a crucial boost in effectiveness for antibiotic treatments used to combat drug-resistant superbugs such as E. coli and Salmonella. Credit: Mason Marino / University of Colorado Boulder
"We are thinking more like the bug," said Anushree Chatterjee, an assistant professor in CHBE and the co-lead author of the study. "This is a novel strategy that plays against the 's normal strength and catalyzes the antibiotic instead."

While other previous antibiotic treatments have proven too indiscriminate in their attack, the quantum dots have the advantage of being able to work selectively on an intracellular level. Salmonella, for example, can grow and reproduce inside host cells. The dots, however, are small enough to slip inside and help clear the infection from within.

"These super-resistant bugs already exist right now, especially in hospitals," said Nagpal. "It's just a matter of not contracting them. But they are one mutation away from becoming much more widespread infections."

Overall, Chatterjee said, the most important advantage of the quantum dot technology is that it offers clinicians an adaptable multifaceted approach to fighting infections that are already straining the limits of current treatments.

"Disease works much faster than we do," she said. "Medicine needs to evolve as well."

Going forward, the researchers envision as a kind of platform technology that can be scaled and modified to combat a wide range of infections and potentially expand to other therapeutic applications.


Explore further

Light-activated nanoparticles prove effective against antibiotic-resistant 'superbugs'

More information: C.M. Courtney el al., "Potentiating antibiotics in drug-resistant clinical isolates via stimuli-activated superoxide generation," Science Advances (2017). DOI: 10.1126/sciadv.1701776 , http://advances.sciencemag.org/content/3/10/e1701776
Journal information: Science Advances

Citation: Light-activated nanoparticles can supercharge current antibiotics (2017, October 4) retrieved 24 June 2019 from https://phys.org/news/2017-10-light-activated-nanoparticles-supercharge-current-antibiotics.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
265 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more